Claims

1. A pharmaceutical composition ~~comprising~~consisting essentially of:
(a) nebivolol and/or a pharmaceutically acceptable salt thereof, and
(b) ~~a liquid vehicle comprising~~ a semifluorinated alkane;

wherein the nebivolol and/or a pharmaceutically acceptable salt thereof is suspended in the ~~liquid vehicle comprising a~~ semifluorinated alkane, and wherein at least 90% of the suspended particles of nebivolol and/or a pharmaceutically acceptable salt thereof have a size of not more than about 15 µm.

2. The pharmaceutical composition according to claim 1, ~~comprising a~~wherein the semifluorinated alkane is a semifluorinated alkane of the formula (II)

$$CF_3(CF_2)_n(CH_2)_mCH_3 \quad (II),$$

wherein n is an integer from 2 to 10 and m is an integer from 2 to 10;

or

wherein n is an integer from 3 to 5 and m is an integer from 4 to 7.

3. The pharmaceutical composition of claim 1 or claim 2, wherein the semifluorinated alkane is selected from the group consisting of 1-perfluorobutyl-pentane ($CF_3(CF_2)_3(CH_2)_4CH_3$; F4H5) and 1-perfluorohexyl-octane ($CF_3(CF_2)_5(CH_2)_7CH_3$, F6H8).

4. The pharmaceutical composition of any one of the preceding claims, wherein the ~~composition is free of water and/or a preservative~~ pharmaceutically acceptable salt of nebivolol is suspended in the semifluorinated alkane.

5. The pharmaceutical composition of any one of the preceding claims, wherein the nebivolol and/or a pharmaceutically acceptable salt thereof is suspended in

the ~~liquid vehicle~~ semifluorinated alkane at a concentration of from 0.3 to 1.5 % (w/v).

6. The pharmaceutical composition of any one of the preceding claims, wherein the nebivolol and/or a pharmaceutically acceptable salt thereof is suspended in the ~~liquid vehicle~~semifluorinated alkane at a concentration of from 0.45 to 1.0 % (w/v).

7. The pharmaceutical composition of any one of the preceding claims, ~~comprising~~ wherein the nebivolol is in the form of nebivolol hydrochloride.

~~8. The pharmaceutical composition of any one of the preceding claims, essentially consisting of nebivolol hydrochloride and 1-perfluorohexyl-octane (F6H8).~~

~~9~~8. The pharmaceutical composition of any one of claims 4 to ~~8~~7, wherein at least about 90% of the suspended particles of the nebivolol and/or a pharmaceutically acceptable salt thereof have a size of not more than about ~~15~~10 µm.

~~10~~9. The pharmaceutical composition of any one of the preceding claims for use as a medicament.

~~11~~10. The pharmaceutical composition for use according to claim ~~10~~9, in the treatment of glaucoma, increased intraocular pressure, ocular hypertension and/or a symptom associated therewith.

~~12~~11. The pharmaceutical composition for use according to claim ~~11~~10, wherein the composition is administered to ~~the~~an eye of a subject~~, preferably up to two times~~ once daily.

12. The pharmaceutical composition according to claim 11, wherein the composition is administered to the eye of a subject in a single dose from about 45 to about 120µg.

13. The pharmaceutical composition for the use according to any one of claims ~~11~~10 ~~or claim~~to 12, wherein the pharmaceutical composition is administered in a dose volume per eye of 8 to 15 µl~~, preferably from about 10 to 12 µl~~.

14. The pharmaceutical composition for the use according to any one of claims 10 to 13 , wherein the pharmaceutical composition is administered in a dose volume per eye of 10 to 12 µl and wherein the composition comprises the nebivolol and/or a pharmaceutically acceptable salt thereof suspended in the semifluorinated alkane in a concentration of at least 0.3% (w/v).

~~14~~15. The pharmaceutical composition for the use according to any one of claims 11 to ~~13~~14, wherein the pharmaceutical composition ~~is administered in a single dose per eye of about 45 to about 120 µg~~comprises nebivolol and/or a pharmaceutically acceptable salt thereof suspended in the semifluorinated alkane in a concentration of from 0.45 to 1.0 % (w/v).

16. The pharmaceutical composition of any one of the preceding claims, wherein the pharmaceutical composition is essentially free of water.

17. The pharmaceutical composition of any one of the preceding claims, wherein the pharmaceutical composition is preservative-free and microbiologically stable.

18. The pharmaceutical composition of claim 17, provided in a multi-dose or single dose format.

19. The pharmaceutical composition of any one of the preceding claims, wherein the composition consists essentially of nebivolol hydrochloride and a semifluorinated alkane selected from F4H5, F4H6, F4H7, F4H8, F5H5, F5H6, F5H7, F5H8, F6H5, F6H6, F6H7, F6H8, F8H8, and F6H10.

20. The pharmaceutical composition of claim 19, wherein the pharmaceutical composition consists essentially of nebivolol hydrochloride and a semifluorinated alkane selected from 1-perfluorobutyl-pentane (F4H5) and 1-perfluorohexyl-octane (F6H8).

21. The pharmaceutical composition of any one of the preceding claims, wherein the pharmaceutical composition is essentially free of water, preservative-free, and substantially free of surfactant.

22. Use of:

(a) nebivolol and/or a pharmaceutically acceptable salt thereof, and
(b) a semifluorinated alkane;

in the manufacture of a pharmaceutical composition for treating glaucoma, increased intraocular pressure, ocular hypertension and/or a symptom associated therewith.

~~15~~23. A kit comprising the pharmaceutical composition according to any one of the ~~preceding~~ claims 1 to 21 and a container for holding the pharmaceutical composition.